Clinical characteristics of male breast cancer from South China： Analysis of 31 cases

doi:10.3969/j.issn.1009-976X.2021.05.011

Abstract

Key words: male breast cancer, retrospective study, clinical characteristics

摘要： 目的总结本院收治的来自华南地区男性乳腺癌的临床及病理特点,为男性乳腺癌的诊疗提供一定的参考。方法收集2010年1月1日至2020年12月30日来我院诊治的乳腺癌的男性病人的相关临床资料。结果 31例患者平均年龄55.87±2.22岁,超重、肥胖人数占比为41.9%,77.4%病理类型为浸润导管癌,90.3%激素受体表达阳性,治疗上均行外科手术切除肿瘤术,并与内分泌治疗、放化疗综合应用,5年生存率为80.6%。结论就当前31例来自华南的男性乳腺患者而言,年纪较轻（中位年龄56岁）及肥胖可能是其临床特点。

关键词: 男性乳腺癌, 回顾性研究, 临床特点

CLC Number:

R737.9

JIN Xiao-yan, QIN Yan-xiang, LIU Shu-qiong, WU Wei. Clinical characteristics of male breast cancer from South China： Analysis of 31 cases[J]. Lingnan Modern Clinics In Surgery, 2021, 21(05): 547-550.

金小岩, 覃延翔, 刘淑琼, 吴畏. 31例男性乳腺癌的临床特点分析[J]. 岭南现代临床外科, 2021, 21(05): 547-550.

References

[1] Abdelwahab Yousef AJ.Male Breast Cancer: Epidemiology and Risk Factors[J]. Semin Oncol, 2017, 44(4): 267-272.
[2] Giordano SH, Cohen DS, Buzdar AU, et al.Breast carcinoma in men: a population-based study[J]. Cancer, 2004, 101(1): 51-57.
[3] Zongo N, Ouédraogo S, Korsaga-Somé N, et al.Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)[J]. World J Surg Oncol, 2018, 16(1): 4.
[4] Silvestri V, Barrowdale D, Mulligan AM, et al.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2[J]. Breast Cancer Res, 2016, 18(1): 15.
[5] 冉然, 吴磊, 王慧, 等. 男性乳腺癌的研究进展[J]. 现代肿瘤医学, 2021, 29(8): 1465-1470.
[6] Gucalp A, Traina TA, Eisner JR, et al.Male breast cancer: a disease distinct from female breast cancer[J]. Breast Cancer Res Treat, 2019, 173(1): 37-48.
[7] Liu N, Johnson KJ, Ma CX.Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis[J]. Clin Breast Cancer, 2018, 18(5): e997-e1002.
[8] Cheang MC, Chia SK, Voduc D, et al.Nielsen, Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer[J]. Natl Cancer Inst, 2009, 101(10): 736-750.
[9] Recht A, Comen EA, Fine RE, et al.Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update[J]. Pract Radiat Oncol, 2016, 6(6): e219-e234.
[10] Yoney A, Kucuk A, Unsal M.Male breast cancer: a retrospective analysis[J]. Cancer Radiother, 2009, 13: 103-107.
[11] 王斌, 连镇, 熊健, 等. 102例男性乳腺癌临床特征及预后分析[J]. 中华普通外科杂志, 2015, 30(1): 23-26.
[12] Fentiman I.Male breast cancer: a review[J]. E cancer Med Sci, 2009, 3: 140.
[13] Harlan LC, Zujewski JA, Goodman MT, Stevens JL.Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival[J]. Cancer, 2010, 116(15): 3558-3368.
[14] Eggemann H, Ignatov A, Smith BJ, et al.Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J]. Breast Cancer Res Treat, 2013, 137(2): 465-470.
[15] Hassett MJ, Somerfield MR, Baker ER, et al.Management of male breast cancer:ASCO guideline[J]. J Clin Oncol, 2020, 38(16): 1849-1863.
[16] Visram H, Kanji F, Dent SF.Endocrine therapy for male breast cancer: rates of toxicity and adherence[J]. Curr Oncol, 2010, 17(5): 17-21.
[17] Zagouri F, Sergentanis TN, Azim HA Jr, et al.Aromatase inhibitors in male breast cancer: a pooled analysis[J]. Breast Cancer Res Treat, 2015, 151(1): 141-147.
[18] Fentiman IS.Male breast cancer is not congruent with the female disease[J]. Crit Rev Oncol Hemato, 2016, 101: 119-124.
[19] Bloom KJ, Govil H, Gattuso P, et al.Status of HER-2 in male and female breast carcinoma[J]. Am J Surg, 2001, 182(4): 389-392.
[20] Gucalp A, Traina TA, Eisner JR, et al.Male breast cancer: a disease distinct from female breast cancer[J]. 2019, 173(1): 37-48.
[21] Wang F, Shu X, Meszoely I, et al.Overall mortality after diagnosis of breast cancer in men vs women[J]. JAMA Oncol, 2019, 5(1): 1589-1596.